Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats

Vaccine

Volumn 27, Issue 50, 2009, Pages 7011-7020

  Laurenzana, Elizabeth M ^a   Hendrickson, Howard P ^b   Carpenter, Dylan ^a   Peterson, Eric C ^a   Gentry, W Brooks ^a   West, Michael ^a   Che, Yingni ^a   Carroll, F Ivy ^c   Owens, S Michael ^a  

^a Department of Surgery   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Methamphetamine; Monoclonal antibody; Passive immunization; Pharmacokinetics; Rat

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G9; MONOCLONAL ANTIBODY 6H4; MONOCLONAL ANTIBODY 6H7; MONOCLONAL ANTIBODY 6H8; MONOCLONAL ANTIBODY 9B11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CONTROLLED STUDY; DRUG HALF LIFE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CROSS REACTIONS; IMMUNIZATION, PASSIVE; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70350571769     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.072     Document Type: Article

References (29)

1. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews Drug Discovery 2 1 (2003) 52-62 [erratum appears in Nat Rev Drug Discov 2003;2(March(3)):240]
2. Berger M., Shankar V., and Vafai A. Therapeutic applications of monoclonal antibodies. American Journal of the Medical Sciences 324 1 (2002) 14-30
3. Kosten T., and Owens S.M. Immunotherapy for the treatment of drug abuse. Pharmacology and Therapeutics 108 1 (2005) 76-85
4. Knapp M.J., and Colburn P.A. Clinical uses of intravenous immune globulin. Clinical Pharmacy 9 7 (1990) 509-529
5. Byrnes-Blake K.A., Laurenzana E.M., Carroll F.I., Abraham P., Gentry W.B., Landes R.D., et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European Journal of Pharmacology 461 2-3 (2003) 119-128
6. Byrnes-Blake K.A., Laurenzana E.M., Landes R.D., Gentry W.B., and Owens S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. European Journal of Pharmacology 521 1-3 (2005) 86-94
7. Laurenzana E.M., Byrnes-Blake K.A., Milesi-Halle A., Gentry W.B., Williams D.K., and Owens S.M. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metabolism and Disposition 31 11 (2003) 1320-1326
8. Cho A.K., Melega W.P., Kuczenski R., and Segal D.S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse (New York, NY) 39 February (2) (2001) 161-166
9. Riviere G.J., Byrnes K.A., Gentry W.B., and Owens S.M. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. The Journal of Pharmacology and Experimental Therapeutics 291 3 (1999) 1220-1226
10. Bazin-Redureau M.I., Renard C.B., and Scherrmann J.M. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. Journal of Pharmacy and Pharmacology 49 3 (1997) 277-281
11. Proksch J.W., Gentry W.B., and Owens S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics 292 3 (2000) 831-837
12. Laurenzana E.M., Gunnell M.G., Gentry W.B., and Owens S.M. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. Journal of Pharmacology and Experimental Therapeutics 306 3 (2003) 1092-1098
13. Peterson E.C., Gunnell M., Che Y., Goforth R.L., Carroll F.I., Henry R., et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. Journal of Pharmacology and Experimental Therapeutics 322 1 (2007) 30-39
14. Owens S.M., Zorbas M., Lattin D.L., Gunnell M., and Polk M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. Journal of Pharmacology and Experimental Therapeutics 246 2 (1988) 472-478
15. Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., and Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Research 31 July (13) (2003) 3784-3788
16. McClurkan M.B., Valentine J.L., Arnold L., and Owens S.M. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. The Journal of Pharmacology and Experimental Therapeutics 266 3 (1993) 1439-1445
17. Hendrickson H., Laurenzana E., and Owens S.M. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS Journal 8 4 (2006) E709-E717
18. Rowland M., and Tozer T.N. Clinical pharamacokinetics concepts and applications. 3rd ed. (1995), Lippincott Willams and Wilkins, Philadelphia
19. Khor S.P., and Mayersohn M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metabolism and Disposition 19 2 (1991) 478-485
20. Montano R.F., and Morrison S.L. Influence of the isotype of the light chain on the properties of IgG. Journal of Immunology 168 1 (2002) 224-231
21. Roskos L.K., Davis C.G., and Schwab G M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Development Research 61 3 (2004) 108-120
22. Gustafson J.M., Dodds S.J., Burgus R.C., and Mercer L.P. Prediction of brain and serum free amino acid profiles in rats fed graded levels of protein. Journal of Nutrition 116 9 (1986) 1667-1681
23. Azzout-Marniche D., Gaudichon C., Blouet C., Bos C., Mathe V., Huneau J.F., et al. Liver glyconeogenesis: a pathway to cope with postprandial amino acid excess in high-protein fed rats?. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 292 4 (2007) R1400-R1407
24. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature Reviews Immunology 7 9 (2007) 715-725
25. Kim J., Bronson C.L., Wani M.A., Oberyszyn T.M., Mohanty S., Chaudhury C., et al. Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice. Experimental Biology and Medicine (Maywood) 233 5 (2008) 603-609
26. Dejaegere A., Choulier L., Lafont V., De Genst E., and Altschuh D. Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study. Biochemistry 44 44 (2005) 14409-14418
27. Jiskoot W., Beuvery E.C., de Koning A.A., Herron J.N., and Crommelin D.J. Analytical approaches to the study of monoclonal antibody stability. Pharmaceutical Research 7 12 (1990) 1234-1241
28. Huang L., Lu J., Wroblewski V.J., Beals J.M., and Riggin R.M. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Analytical Chemistry 77 5 (2005) 1432-1439
29. Gentry W.B., Laurenzana E.M., Williams D.K., West J.R., Berg R.J., Terlea T., et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. International Immunopharmacology 6 6 (2006) 968-977